This week, React19 announced the launch of ‘This Is Our Shot,’ a nationwide campaign to raise over $1 million for additional care grants. Two anonymous benefactors have pledged $250,000 each, creating ...
HomeInherit provides ethical and transparent financial solutions that allow seniors to unlock home equity without taking on debt. With a focus on trust, family inclusion, and clear communication, ...
SRx Health Solutions, Inc. (NYSE American: SRXH) (the “Company”) today announced the Company has been notified by the NYSE American of unusual trading activity of its Common Shares on November 6, 2025 ...
The Company anticipates no change to the preliminary sales results for the third quarter ended September 30, 2025 that were disclosed on October 7, 2025. The Company expects to file its Quarterly ...
2025 Financial Guidance Sight Sciences raises its revenue guidance expectations for full year 2025 to $76.0 million to $78.0 million, representing a 2% to 5% decline compared to full year 2024 revenue ...
NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that Heather Turner, Chief Executive Officer, will present at ...
Net revenue increased 35% to $4.8 million compared to $3.5 million in the third quarter of 2024 Net income increased 84% to $337,000, compared to $183,000 in the third quarter of 2024 Adjusted EBITDA ...
SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company or Cidara), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc ...
Seer will host a conference call to discuss the third quarter 2025 financial results on Thursday, November 6, 2025 at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can ...
Coherus Oncology, Inc. (Nasdaq: CHRS), today reported financial results for the third quarter ended September 30, 2025 and provided an overview of recent business highlights. “In Q3 2025, we gained ...
Operating results Total operating expenses were approximately $12.1 million for the three months ended September 30, 2025, a decrease of $0.7 million from $12.8 million for the same period in 2024.
R&D Expenses: Research and development expenses for the quarter ended September 30, 2025, were $9.4 million, compared to $9.7 million for the quarter ended September 30, 2024. The expenses were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback